Market Spotlight: Acne
Market Spotlight: Acne
This Market Spotlight report covers the Acne market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.e forecasts.
This Market Spotlight report covers the Acne market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
- Datamonitor Healthcare estimates that in 2016, there were approximately 615 million prevalent cases of acne worldwide, and forecasts that number to increase to 673 million prevalent cases by 2025.
- Approved drugs in the acne space focus on a wide variety of targets. These drugs are commonly administered via the oral and topical routes.
- The majority of industry-sponsored drugs in active clinical development for acne are in Phase II, with only two drugs in NDA/BLA phase.
- Therapies in mid-to-late-stage development for acne focus on a variety of targets. The majority of the drugs in mid-to-late-stage development are administered via the topical route, with the remainder being oral, subcutaneous, intranasal, or intravenous formulations.
- High-impact upcoming events for drugs in the acne space include topline Phase II and Phase III trial results, as well as the FDA’s decisions on NDAs.
- There were 20 licensing and asset acquisition activities involving acne drugs during 2013–18, seven of which occurred in 2014. The exclusive 2017 license agreement between XOMA and Novartis, worth $454m for the global rights to XOMA’s program relating to gevokizumab, was the largest deal during the 2013–18 period.
- Yaz’s sales ranked highest among drugs available for acne during 2012–17. The clinical trials distribution across Phase I–IV indicates that the majority of trials for acne have been in late phases of development, with 56.5% of trials in Phase III–IV, and 43.5% in Phase I–II.
- The US has a substantial lead in the number of acne clinical trials globally. Germany leads the major EU markets, while Japan has the top spot in Asia.
- Clinical trial activity in the acne space is dominated by completed trials. GlaxoSmithKline has the highest number of completed clinical trials for acne, with 35 trials.
- GlaxoSmithKline leads the industry sponsors with by far the highest number of clinical trials for acne, followed by Allergan and Photocure.
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
8 Topical therapy
8 Systemic therapy
9 Physical treatments
13 MARKETED DRUGS
18 Approvals by country
22 PIPELINE DRUGS
29 KEY UPCOMING EVENTS
30 KEY REGULATORY EVENTS
30 Differin Extends With Cleanser, Moisturizer, Biore Adds Foam In OTC Skin Care
30 Galderma Pioneers NDA Path Into OTC Acne Treatment Market
31 LICENSING AND ASSET ACQUISITION DEALS
31 Sato licenses Japanese rights to Novan’s acne candidate SB204
32 PARENT PATENTS
33 REVENUE OPPORTUNITY
36 CLINICAL TRIAL LANDSCAPE
37 Sponsors by status
38 Sponsors by phase
38 Dermira Ends Acne Program After Phase III Failure, Tries To Keep Focus On Hyperhidrosis Drug
39 Acne Pipeline Yields Three Disappointments, One Win So Far In 2017
39 Xenon Down On Novel Acne Treatment Failure
40 Prescription information
LIST OF FIGURES
12 Figure 1: Trends in prevalent cases of acne, 2016–25
22 Figure 2: Pipeline drugs for acne in the US
22 Figure 3: Pipeline drugs for acne, by company
23 Figure 4: Pipeline drugs for acne, by drug type
23 Figure 5: Pipeline drugs for acne, by classifications
29 Figure 6: Key upcoming events in acne
31 Figure 7: Licensing and asset acquisition deals in acne
32 Figure 8: Parent patents in acne
36 Figure 9: Clinical trials in acne
36 Figure 10: Top 10 drugs for clinical trials in acne
37 Figure 11: Top 10 companies for clinical trials in acne
37 Figure 12: Trial locations in acne
38 Figure 13: Acne trials sponsors, by status
38 Figure 14: Acne trials sponsors, by phase
LIST OF TABLES
11 Table 1: Prevalent cases of acne, 2016–25
14 Table 2: Marketed drugs for acne
19 Table 3: Approvals by country for acne
24 Table 4: Pipeline drugs for acne in the US
34 Table 5: Historical global sales, by drug ($m), 2012–17
35 Table 6: Forecasted global sales, by drug ($m), 2018–22
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email email@example.com for further help or assistance.